Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Osteoporosis, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/23/2019 |
| Start Date: | January 28, 2019 |
| End Date: | October 2021 |
Assessment of Vertebral Fracture Risk Using VFA and Vertebral Strength Assessment With DXA-Finite Element Analysis in Liver Transplant Recipients in Pretransplant Period
The Investigators hypothesize that VFA+ DXA is as effective in evaluation of asymptotic
vertebral fractures compared to the current gold standard of spine x-ray. In addition, bone
turnover markers in transplant patients are unknown. The investigators want to investigate
bone turnover markers (Beta CTX and P1NP) as markers of bone health in patients listed for
liver transplant.
vertebral fractures compared to the current gold standard of spine x-ray. In addition, bone
turnover markers in transplant patients are unknown. The investigators want to investigate
bone turnover markers (Beta CTX and P1NP) as markers of bone health in patients listed for
liver transplant.
Inclusion criteria
- First time liver transplant candidates deemed too early for liver transplant
- 24 hour urine Creatinine clearance of > 40 mg/dl. However bone turnover markers (beta
CTx and P1NP) will be measured only in those with creatinine clearance >60mg/dl
Exclusion criteria
- Patients with prior solid organ transplantation
- Liver/kidney combination will be excluded
- Patients with 24 hr. urine creatinine clearance < 40mL/minute
- Patients who have been on osteoporosis medications - Bisphosphonates [Fosamax
(Alendronate), Actonel (Risedronate), Boniva (Ibandronate), or Reclast (Zoledronic
acid)] Teriparatide (Forteo), Abaloparatide (Tymlos), Denosumab (Prolia), within the
past 5 years
- Use of other systemic medications that can effect bone remodeling including sex
hormone replacement therapy (estrogen or testosterone), calcitonin, androgen
deprivation therapy, aromatase inhibitors, or SERMS in the past 6 months
- Underlying disease that significantly impacts bone metabolism such as primary
hyperparathyroidism, hyperthyroidism, Paget's disease of bone, fibrous dysplasia, or
malignancies with skeletal metastases
We found this trial at
2
sites
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Click here to add this to my saved trials